SELLAS Life Sciences Group Inc (SLS)
1.33
-0.02
(-1.48%)
USD |
NASDAQ |
May 03, 16:00
1.315
-0.02
(-1.13%)
After-Hours: 20:00
SELLAS Life Sciences Group Cash from Financing (Quarterly): 3.386M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 3.386M |
| September 30, 2023 | 0.054M |
| June 30, 2023 | -0.029M |
| March 31, 2023 | 18.90M |
| December 31, 2022 | 0.929M |
| September 30, 2022 | 0.107M |
| June 30, 2022 | 23.00M |
| March 31, 2022 | 0.047M |
| December 31, 2021 | 0.05M |
| September 30, 2021 | 2.242M |
| June 30, 2021 | 6.782M |
| March 31, 2021 | 3.00M |
| December 31, 2020 | 23.68M |
| September 30, 2020 | 8.492M |
| June 30, 2020 | -0.025M |
| March 31, 2020 | 6.30M |
| December 31, 2019 | 2.319M |
| September 30, 2019 | 0.189M |
| June 30, 2019 | 14.83M |
| March 31, 2019 | 2.23M |
| December 31, 2018 | -0.076M |
| September 30, 2018 | 14.25M |
| June 30, 2018 | 4.208M |
| March 31, 2018 | 4.739M |
| December 31, 2017 | -15.54M |
| Date | Value |
|---|---|
| September 30, 2017 | 15.41M |
| June 30, 2017 | 5.655M |
| March 31, 2017 | 0.00 |
| December 31, 2016 | -16.26M |
| September 30, 2016 | 17.13M |
| June 30, 2016 | -3.628M |
| March 31, 2016 | 19.25M |
| December 31, 2015 | -1.009M |
| September 30, 2015 | -0.759M |
| June 30, 2015 | 4.329M |
| March 31, 2015 | 41.28M |
| December 31, 2014 | 9.846M |
| September 30, 2014 | -0.325M |
| June 30, 2014 | 0.019M |
| March 31, 2014 | 14.72M |
| December 31, 2013 | 7.687M |
| September 30, 2013 | 37.74M |
| June 30, 2013 | 10.43M |
| March 31, 2013 | 0.092M |
| December 31, 2012 | 22.56M |
| September 30, 2012 | 0.36M |
| June 30, 2012 | 17.36M |
| March 31, 2012 | 2.153M |
| December 31, 2011 | 0.01M |
| September 30, 2011 | 1.173M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.029M
Minimum
Jun 2023
23.68M
Maximum
Dec 2020
6.013M
Average
2.319M
Median
Dec 2019
Cash from Financing (Quarterly) Benchmarks
| Geron Corp | 147.80M |
| Immuneering Corp | 0.0078M |
| Protagonist Therapeutics Inc | 0.527M |
| Akebia Therapeutics Inc | -1.29M |
| Moderna Inc | 14.00M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -4.825M |
| Free Cash Flow | -36.91M |
| Free Cash Flow Per Share (Quarterly) | -0.1566 |
| Free Cash Flow Yield | -99.96% |